ACHV Share Price Performance
US$7.25
4.70 (184.31%)
47.5% undervalued intrinsic discount
US$13.80
Fair Value
Price US$7.25
AnalystConsensusTarget US$13.80
AnalystHighTarget US$21.00
AnalystLowTarget US$9.00
Fair ValueUS$13.80
Share Pricen/a
Achieve Life Sciences, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 36 Fair Values set on narratives written by author
ACHV Community Narratives
AN
Fair Value
·Fair Value US$13.8 47.5% undervalued intrinsic discount
Regulatory Tailwinds And Public Health Demand Will Support This Nicotine Cessation Opportunity
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value
·Fair Value US$21 65.5% undervalued intrinsic discount
FDA Priority Voucher And Smoking Cessation Tailwinds Will Transform This Undervalued Biotech Story
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value US$9 19.4% undervalued intrinsic discount
Regulatory And Commercial Hurdles Will Test Smoking Cessation Catalyst Yet Long Term Potential Remains
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Regulatory Tailwinds And Public Health Demand Will Support This Nicotine Cessation Opportunity
A small drugmaker is trying to bring a new quit-smoking and quit-vaping medicine to market, helped by regulators and a big unmet need among people who want to stop. The big question is whether approval, funding, and real-world demand arrive fast enough to beat entrenched alternatives and turn the idea into a viable product launch.Read more
AN
US$13.8
47.5% undervalued intrinsic discount
Fair Value
Profit Margin
23.05%
Future PE
50.59x
Price in 2029
US$0
Regulatory And Commercial Hurdles Will Test Smoking Cessation Catalyst Yet Long Term Potential Remains
Achieve Life Sciences is trying to bring a new medicine for quitting smoking—and potentially vaping—to market, but the path runs through tough approval, launch, and insurance coverage hurdles that could slow real-world uptake. The upside rests on whether it can prove a lean, digital-first launch model and reliable manufacturing while staying funded long enough to reach broad prescribing.Read more
AN
US$9
19.4% undervalued intrinsic discount
Fair Value
Profit Margin
18.92%
Future PE
117.45x
Price in 2029
US$0
FDA Priority Voucher And Smoking Cessation Tailwinds Will Transform This Undervalued Biotech Story
Achieve Life Sciences is nearing a make-or-break moment as its quit-smoking pill heads toward an FDA decision, which could turn it from a research-stage company into one that can finally sell a product. A faster path for a vaping-focused version and a data-driven launch plan could widen the opportunity, but delays, funding needs, or slow doctor and insurer uptake could derail the story.Read more
AN
US$21
65.5% undervalued intrinsic discount
Fair Value
Profit Margin
50.79%
Future PE
16.75x
Price in 2029
US$0
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
ACHV: FDA Resubmission And Potential First New Cessation Therapy Could Reignite Upside
Fair Value: US$13.8 47.5% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ACHV: FDA Response And Index Inclusion Will Shape Smoking Cessation Outlook
Fair Value: US$9 19.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ACHV: Manufacturing Progress And Margin Potential Will Support Bullish Thesis
Fair Value: US$21 65.5% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Achieve Life Sciences, Inc. Key Details
About ACHV
- Founded
- n/a
- Employees
- 28
- CEO
- WebsiteView website
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
